Publications by authors named "Taylor A Rives"
Article Synopsis
- A 74-year-old woman was diagnosed with stage IV high grade serous ovarian cancer and malignant pleural effusion, showing PDL1 positivity.
- After starting standard chemotherapy (carboplatin and paclitaxel), she developed an itchy rash that was found to be a non-resectable in situ cutaneous squamous cell carcinoma (cSCC).
- A PD1-inhibitor was added to her treatment, leading to a complete response of both the ovarian cancer and the cSCC by the time of surgery.
Article Synopsis
- STK11 gene mutations are linked to Peutz-Jeghers syndrome, which increases the risk of various cancers, including gastrointestinal and breast cancers.
- The article describes a rare case of an STK11-associated adnexal tumor in a 39-year-old woman who previously had malignant mesothelioma.
- The need for careful diagnosis and further analysis of STK11 adnexal tumors is highlighted due to their uncommon occurrence and unclear pathology.
Purpose: Tumor next-generation sequencing (NGS) testing identifies possible germline pathogenic variants (PGPVs), creating a dilemma for appropriate recognition, triage, and management. The objective of this study was to determine the clinical utility of an institutional molecular tumor board (MTB) in assessing tumor NGS reports for PGPVs.
Methods: Our institutional MTB reviews all NGS reports to provide treatment and further testing recommendations, including genetic counseling referral and consideration of genetic testing (GC/GT).
Article Synopsis
- - Patients with platinum-resistant epithelial ovarian cancer have limited treatments, and those with hypersensitivity to paclitaxel face additional challenges, as paclitaxel can cause severe allergic reactions due to its high incidence of hypersensitivity.
- - Mirvetuximab soravtansine-gynx (MIRV) offers a targeted treatment option for this patient demographic, though both MIRV and paclitaxel target microtubules, raising concerns about potential cross-reactivity.
- - A case study of a 33-year-old woman with a severe allergy to paclitaxel highlights that, with proper precautions, patients with a history of anaphylaxis to paclitaxel could safely receive MIRV, suggesting
Objectives: Optimal management of obese patients with early-stage cervical cancer is debated despite evidence of non-inferior survival in obese patients undergoing radical hysterectomy with pelvic lymphadenectomy (RH) compared to primary radiation with or without radiosensitizing chemotherapy (RT). Objectives included describing patient factors affecting disposition to RH versus RT; comparing RH outcomes for obese (BMI >30 mg/m) and non-obese patients; and comparing differences in recurrence free survival (RFS) and overall survival (OS).
Methods: This was a single institution cohort study of all cervical cancer patients who underwent RH or were candidates for RH based on clinical stage.
Purpose: The purpose of this study was to assess the impact of implementing a Nurse Navigator (NN) to improve the rate and timeliness of molecular tumor testing.
Methods: This is an evaluation of the impact of education sessions, consensus building, and NN implementation for molecular tumor testing in patients with epithelial ovarian cancer. The NNs' responsibilities included attending tumor boards and ensuring Next Generation Sequencing (NGS) is ordered, reviewed, and coordinated for appropriate patients.